Telix Pharmaceuticals Limited (OTCMKTS:TLPPF) Short Interest Up 47.1% in August

Telix Pharmaceuticals Limited (OTCMKTS:TLPPF) saw a large increase in short interest in August. As of August 31st, there was short interest totalling 1,341,500 shares, an increase of 47.1% from the August 15th total of 912,200 shares. Based on an average trading volume of 9,200 shares, the short-interest ratio is presently 145.8 days.

Telix Pharmaceuticals Price Performance

TLPPF stock traded down $0.74 during mid-day trading on Friday, hitting $12.75. 820 shares of the company were exchanged, compared to its average volume of 7,996. The firm has a fifty day simple moving average of $12.64 and a 200 day simple moving average of $10.85. Telix Pharmaceuticals has a twelve month low of $5.30 and a twelve month high of $14.59.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its products portfolio include Illuccix for the treatment of prostate cancer;, TLX591, a radio antibody-drug conjugate, which is in phase 3 clinical trial for the treatment of prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma.